223 related articles for article (PubMed ID: 26376461)
1. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with breast cancer treated with HER2 blockade.
Wu J; Qiu K; Zhu J; Li J; Lin Y; He Z; Li G
Breast; 2015 Dec; 24(6):699-704. PubMed ID: 26376461
[TBL] [Abstract][Full Text] [Related]
2. Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials.
Hao S; Tian W; Gao B; Jiang Y; Zhang X; Zhang S; Guo L; Zhao J; Zhang G; Hu C; Yan J; Luo D
Oncotarget; 2017 Mar; 8(12):19923-19933. PubMed ID: 28199966
[TBL] [Abstract][Full Text] [Related]
3. Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.
Valachis A; Nearchou A; Polyzos NP; Lind P
Int J Cancer; 2013 Nov; 133(9):2245-52. PubMed ID: 23629633
[TBL] [Abstract][Full Text] [Related]
4. Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review.
Zhang X; Zhang XJ; Zhang TY; Yu FF; Wei X; Li YS; He J
BMC Cancer; 2014 Aug; 14():625. PubMed ID: 25164542
[TBL] [Abstract][Full Text] [Related]
5. Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis.
Long HD; Lin YE; Zhang JJ; Zhong WZ; Zheng RN
Oncologist; 2016 May; 21(5):547-54. PubMed ID: 27026675
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
Nagayama A; Hayashida T; Jinno H; Takahashi M; Seki T; Matsumoto A; Murata T; Ashrafian H; Athanasiou T; Okabayashi K; Kitagawa Y
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25224562
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.
Valachis A; Nearchou A; Lind P; Mauri D
Breast Cancer Res Treat; 2012 Oct; 135(3):655-62. PubMed ID: 22875745
[TBL] [Abstract][Full Text] [Related]
8. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
9. Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis.
Li H; Fu W; Gao X; Xu Q; Wu H; Tan W
Tumour Biol; 2014 May; 35(5):4077-85. PubMed ID: 24375251
[TBL] [Abstract][Full Text] [Related]
10. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
Sabatier R; Gonçalves A
Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
[TBL] [Abstract][Full Text] [Related]
11. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis.
Drucker AM; Wu S; Dang CT; Lacouture ME
Breast Cancer Res Treat; 2012 Sep; 135(2):347-54. PubMed ID: 22782294
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis.
Yu Q; Zhu Z; Liu Y; Zhang J; Li K
PLoS One; 2015; 10(5):e0127404. PubMed ID: 25993646
[TBL] [Abstract][Full Text] [Related]
14. Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
Saini KS; Azim HA; Metzger-Filho O; Loi S; Sotiriou C; de Azambuja E; Piccart M
Breast; 2011 Oct; 20 Suppl 3():S20-7. PubMed ID: 22015288
[TBL] [Abstract][Full Text] [Related]
15. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
18. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
19. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.
Olson EM; Abdel-Rasoul M; Maly J; Wu CS; Lin NU; Shapiro CL
Ann Oncol; 2013 Jun; 24(6):1526-33. PubMed ID: 23463626
[TBL] [Abstract][Full Text] [Related]
20. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]